Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia

被引:47
作者
Carreras, E
Jiménez, M
Gómez-García, V
de la Cámara, R
Martín, C
Martínez, F
Iriondo, A
Sanz, G
Cañizo, C
Cabrera, R
Sierra, J
Vallejo, C
López, J
Martínez, C
Rovira, M
Fernández-Rañada, JM
Torres, A
机构
[1] Hosp Clin Barcelona, Dept Hematol, BMT Unit, IDIBAPS, E-08036 Barcelona, Spain
[2] IDIBAPS, Spanish Bone Marrow Donor Registry REDMO, Barcelona, Spain
[3] Hosp Princesa, Madrid, Spain
[4] Hosp Reina Sofia, Cordoba, Spain
[5] Hosp Marques Valdecilla, Santander, Spain
[6] Hosp La Fe, Valencia, Spain
[7] Hosp Univ Salamanca, Salamanca, Spain
[8] Clin Puerta de Hierro, Madrid, Spain
[9] Hosp Sant Creu & Sant Pau, Barcelona, Spain
[10] Hosp Univ Murcia, Murcia, Spain
[11] Hosp Ramon y Cajal, E-28034 Madrid, Spain
关键词
chronic myeloid leukaemia; haematopoietic cell transplantation; unrelated donor HCT;
D O I
10.1038/sj.bmt.1705195
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We analysed the outcome of 92 consecutive unrelated donor haematopoietic cell transplantations (UD-HCTs) performed in Spain to treat adult patients with CML in the first chronic phase (1CP). Patients' and donors' median age was 32 (15-49) and 36 (22-56) years, respectively. In all, 73 pairs (79%) matched for A, B +/- C and DRB1 +/- DQB1 loci and 19 had >= 1 mismatch. Their probability of survival and disease-free survival at 4 years were 50 and 46%, respectively. Pretransplant factors associated with a better survival were patient age < 25 years (P = 0.035), donor age <= 36 years (P = 0.012), use of cyclosporine since day -7 (P = 0.001), and matching 8/8, 9/10 or 10/10 loci at allele level (P = 0.003). In multivariate analysis only donor age (P = 0.003; RR = 3.1 (95% CI: 1.3-7.1)) and degree of HLA-matching (P = 0.009; RR: 7.7 (95% CI: 1.8-33)) maintained their significance. The addition of these two variables to the EBMT prognostic score allowed an adequate risk assessment for patients receiving a UD-HCT during 1CP. Our analysis shows that in patients with a young and fully allele-matched donor, UD-HCT should be considered in the initial therapeutic algorithm due to its excellent outcome (92% survival at 2 years).
引用
收藏
页码:33 / 40
页数:8
相关论文
共 20 条
[1]  
Anasetti C, 2003, HAEMATOLOGICA, V88, P246
[2]  
APPELBAUM FR, 2004, THOMAS HEMATOPOIETIC, P1007
[3]   CYTOMEGALOVIRUS IMMUNE GLOBULIN AND SERONEGATIVE BLOOD PRODUCTS TO PREVENT PRIMARY CYTOMEGALOVIRUS-INFECTION AFTER MARROW TRANSPLANTATION [J].
BOWDEN, RA ;
SAYERS, M ;
FLOURNOY, N ;
NEWTON, B ;
BANAJI, M ;
THOMAS, ED ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (16) :1006-1010
[4]  
Carreras E, 2000, HAEMATOLOGICA, V85, P530
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia [J].
Elmaagacli, AH ;
Basoglu, S ;
Peceny, R ;
Trenschel, R ;
Ottinger, H ;
Lollert, A ;
Runde, V ;
Grosse-Wilde, H ;
Beelen, DW ;
Schaefer, UW .
BLOOD, 2002, 99 (04) :1130-1135
[7]   Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome [J].
Flomenberg, N ;
Baxter-Lowe, LA ;
Confer, D ;
Fernandez-Vina, M ;
Filipovich, A ;
Horowitz, M ;
Hurley, C ;
Kollman, C ;
Anasetti, C ;
Noreen, H ;
Begovich, A ;
Hildebrand, W ;
Petersdorf, E ;
Schmeckpeper, B ;
Setterholm, M ;
Trachtenberg, E ;
Williams, T ;
Yunis, E ;
Weisdorf, D .
BLOOD, 2004, 104 (07) :1923-1930
[8]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[9]   Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation [J].
Gratwohl, A ;
Hermans, J ;
Goldman, JM ;
Arcese, W ;
Carreras, E ;
Devergie, A ;
Frassoni, F ;
Gahrton, G ;
Kolb, H ;
Niederwieser, D ;
Ruutu, T ;
Vernant, JP ;
de Witte, T ;
Apperley, J .
LANCET, 1998, 352 (9134) :1087-1092
[10]  
GREY RJ, 1988, ANN STAT, V16, P1141